AI Article Synopsis
- Mesenchymal stem cells (MSCs) are derived from embryonic mesoderm and can develop into various connective tissues, but when transformed, they can become aggressive sarcomas due to specific chromosomal changes.
- These transformed cells typically remain in a proliferative state, unable to mature, due to the abnormal activity of oncogenes that interfere with their development.
- Targeting the epigenetic changes caused by these oncogenes, possibly through agents that promote differentiation, could improve treatment outcomes for patients with sarcoma.
Article Abstract
Mesenchymal stem cells (MSCs) originate from embryonic mesoderm and give rise to the multiple lineages of connective tissues. Transformed MSCs develop into aggressive sarcomas, some of which are initiated by specific chromosomal translocations that generate fusion proteins with potent oncogenic properties. The sarcoma oncogenes typically prime MSCs through aberrant reprogramming. They dictate commitment to a specific lineage but prevent mature differentiation, thus locking the cells in a state of proliferative precursors. Deregulated expression of lineage-specific transcription factors and controllers of chromatin structure play a central role in MSC reprogramming and sarcoma pathogenesis. This suggests that reversing the epigenetic aberrancies created by the sarcoma oncogenes with differentiation-related reagents holds great promise as a beneficial addition to sarcoma therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.semcancer.2014.05.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!